Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Pazopanib in Imatinib Refractory or Intolerant Gastrointestinal Stromal Tumors (GIST)

Gastrointestinal Stromal Tumor

Terminated

2

Start Date 07/01/2011

Age of Trial (yrs) 12.8

Gleevec-resistant

KIT/PDGFRA inhibitor+ VEGF inhibitor (TKI)

Block KIT + Block blood vessel growth

Specifically GIST and only GIST

SU-05172011-7781, GIST0003, RR2002/00017/09

Stanford University

Maria Ahern

mahern@stanford.edu

650-725-6413

Oral

This study is being done to gather information about the safety (any harmful effects) and effectiveness (usefulness) of Pazopanib in the treatment of Gastrointestinal Stroma Tumors (GIST) that cannot be treated by surgery or has spread to other organs. The Food and Drug Administration (FDA) have approved Pazopanib for the treatment of advanced kidney cancer but it is not approved for the treatment of GIST. The investigators hope to learn about the safety and usefulness (effectiveness) of Pazopanib for patients with GIST.